Back

Nxera Pharma receives $8.6 million milestone payment from Centessa

Verifying
  • Centessa Pharmaceuticals achieved a late-stage milestone in its selective OX2R agonist portfolio.
  • $8.6 million will be paid to Nxera and recognized in third-quarter 2026 revenue.
  • Lilly completed its Centessa acquisition on June 24, 2026, gaining the OX2R pipeline.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.